Brief: Cocrystal Pharma FY Net Income USD -8.831 Million
31/03/2026 13:00
Mar 31 (Reuters) - Cocrystal Pharma FY operating expenses USD 9.019 million. FY basic EPS USD -0.78 FY operating income USD -9.019 million
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway